Upadacitinib is an oral JAK1 inhibitor that has been found to have significant therapeutic effects in the treatment of rheumatoid arthritis, moderate to severe atopic dermatitis, and ankylosing spondylitis (11). This evidence concerns the gene JAK1 and atopic eczema.